“Nuts and Bolts” of Laboratory Evaluation of Angioedema

[1]  M. Triggiani,et al.  Elevated plasma levels of vascular permeability factors in C1 inhibitor‐deficient hereditary angioedema , 2016, Allergy.

[2]  B. Wolf,et al.  Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels. , 2016, The Journal of allergy and clinical immunology.

[3]  G. Colonna‐Romano,et al.  Growth factors and IL-17 in hereditary angioedema , 2016, Clinical and Experimental Medicine.

[4]  M. Cicardi,et al.  Angioedema Phenotypes: Disease Expression and Classification , 2016, Clinical Reviews in Allergy & Immunology.

[5]  M. Speletas,et al.  Genetics of Hereditary Angioedema Revisited , 2016, Clinical Reviews in Allergy & Immunology.

[6]  H. Farkas,et al.  Atrial natriuretic peptide as a novel biomarker of hereditary angioedema. , 2016, Clinical immunology.

[7]  S. Gelmini,et al.  Second SPIDIA-DNA External Quality Assessment (EQA): Influence of pre-analytical phase of blood samples on genomic DNA quality. , 2016, Clinica chimica acta; international journal of clinical chemistry.

[8]  H. Farkas,et al.  Novel Vasoregulatory Aspects of Hereditary Angioedema: the Role of Arginine Vasopressin, Adrenomedullin and Endothelin-1 , 2016, Journal of Clinical Immunology.

[9]  H. Farkas,et al.  Neutrophil activation during attacks in patients with hereditary angioedema due to C1-inhibitor deficiency , 2015, Orphanet Journal of Rare Diseases.

[10]  Á. Szilágyi,et al.  F12‐46C/T polymorphism as modifier of the clinical phenotype of hereditary angioedema , 2015, Allergy.

[11]  D. Hamann,et al.  ELISA to measure neutralizing capacity of anti-C1-inhibitor antibodies in plasma of angioedema patients. , 2015, Journal of immunological methods.

[12]  K. Skjødt,et al.  The Levels of the Lectin Pathway Serine Protease MASP-1 and Its Complex Formation with C1 Inhibitor Are Linked to the Severity of Hereditary Angioedema , 2015, The Journal of Immunology.

[13]  J. Skopál,et al.  Comprehensive study into the activation of the plasma enzyme systems during attacks of hereditary angioedema due to C1-inhibitor deficiency , 2015, Orphanet Journal of Rare Diseases.

[14]  L. Bouillet,et al.  Towards a specific marker for acute bradykinin-mediated angioedema attacks: a literature review , 2015, European Journal of Dermatology.

[15]  M. Nöthen,et al.  Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. , 2015, The Journal of clinical investigation.

[16]  S. Quirce,et al.  Utility of specific IgE to Ara h 6 in peanut allergy diagnosis. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[17]  K. Bork,et al.  Hereditary angioedema with normal C1‐INH with versus without specific F12 gene mutations , 2015, Allergy.

[18]  W. Lumry,et al.  Comparison of chromogenic and ELISA functional C1 inhibitor tests in diagnosing hereditary angioedema. , 2015, The journal of allergy and clinical immunology. In practice.

[19]  H. Longhurst,et al.  Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk , 2015, Allergy.

[20]  H. Farkas,et al.  A novel assay to diagnose hereditary angioedema utilizing inhibition of bradykinin‐forming enzymes , 2015, Allergy.

[21]  M. Cicardi,et al.  High‐molecular‐weight kininogen cleavage correlates with disease states in the bradykinin‐mediated angioedema due to hereditary C1‐inhibitor deficiency , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[22]  H. Farkas,et al.  Activation of the ficolin-lectin pathway during attacks of hereditary angioedema. , 2014, The Journal of allergy and clinical immunology.

[23]  M. Borum,et al.  Hereditary angioedema: what the gastroenterologist needs to know , 2014, Clinical and experimental gastroenterology.

[24]  C. Hack,et al.  C‐reactive protein levels in hereditary angioedema , 2014, Clinical and experimental immunology.

[25]  T. Zuberbier,et al.  The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. , 2014, Allergy.

[26]  H. Farkas,et al.  Endothelial cell activation during edematous attacks of hereditary angioedema types I and II. , 2014, The Journal of allergy and clinical immunology.

[27]  G. Romano,et al.  Upregulation of cytokines and IL-17 in patients with hereditary angioedema , 2014, Clinical chemistry and laboratory medicine.

[28]  M. Triggiani,et al.  Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group , 2014, Allergy.

[29]  James Brian Byrd,et al.  Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema , 2013, Pharmacogenetics and genomics.

[30]  H. ten Cate,et al.  Ongoing Contact Activation in Patients with Hereditary Angioedema , 2013, PloS one.

[31]  S. Cichon,et al.  Enzymatic Assays for the Diagnosis of Bradykinin-Dependent Angioedema , 2013, PloS one.

[32]  E. Sturrock,et al.  Association of B2 Receptor Polymorphisms and ACE Activity With ACE Inhibitor–Induced Angioedema in Black and Mixed‐Race South Africans , 2013, Journal of clinical hypertension.

[33]  A. Dopazo,et al.  Disease-modifying factors in hereditary angioedema: an RNA expression-based screening , 2013, Orphanet Journal of Rare Diseases.

[34]  H. Farkas,et al.  An abdominal attack of hereditary angio-oedema , 2013, The Lancet.

[35]  W. V. van Heerde,et al.  Alterations of coagulation and fibrinolysis in patients with angioedema due to C1‐inhibitor deficiency , 2012, Clinical and experimental immunology.

[36]  H. Farkas,et al.  Endothelial Cell Function in Patients with Hereditary Angioedema: Elevated Soluble E-selectin Level During Inter-attack Periods , 2012, Journal of Clinical Immunology.

[37]  P. Giclas,et al.  Update on laboratory tests for the diagnosis and differentiation of hereditary angioedema and acquired angioedema. , 2011, Allergy and asthma proceedings.

[38]  C. Drouet,et al.  Hereditary angioedema: key role for kallikrein and bradykinin in vascular endothelial-cadherin cleavage and edema formation. , 2011, The Journal of allergy and clinical immunology.

[39]  H. Farkas,et al.  Parameters of the classical complement pathway predict disease severity in hereditary angioedema. , 2011, Clinical immunology.

[40]  K. Strimbu,et al.  What are biomarkers? , 2010, Current opinion in HIV and AIDS.

[41]  James Brian Byrd,et al.  Association of angiotensin‐converting enzyme inhibitor‐associated angioedema with transplant and immunosuppressant use , 2010, Allergy.

[42]  H. Farkas,et al.  Management of upper airway edema caused by hereditary angioedema , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[43]  A. Kaplan,et al.  The bradykinin-forming cascade and its role in hereditary angioedema. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[44]  H. Farkas,et al.  Baseline level of functional C1-inhibitor correlates with disease severity scores in hereditary angioedema. , 2010, Clinical immunology.

[45]  P. Lachmann.  Preparing serum for functional complement assays. , 2010, Journal of immunological methods.

[46]  B. Materson,et al.  Inherent inaccuracies and potential utility of race/ethnicity labeling in the treatment of hypertension. , 2009, Journal of the American Society of Hypertension : JASH.

[47]  T. Buclin,et al.  Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema. , 2009, Hypertension.

[48]  F. Marceau,et al.  Angiotensin converting enzyme inhibitor induced angio‐oedema: a review of the pathophysiology and risk factors , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[49]  K. Bork,et al.  Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. , 2009, The Journal of allergy and clinical immunology.

[50]  A. Bellatorre,et al.  Plasma biomarkers of acute attacks in patients with angioedema due to C1‐inhibitor deficiency , 2009, Allergy.

[51]  H. Joller-jemelka,et al.  Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations. , 2008, Journal of immunological methods.

[52]  P. Gál,et al.  Depressed activation of the lectin pathway of complement in hereditary angioedema , 2008, Clinical and experimental immunology.

[53]  E. Rondonotti,et al.  Successful resolution of bowel obstruction in a patient with hereditary angioedema , 2008, European journal of gastroenterology & hepatology.

[54]  M. López-Trascasa,et al.  Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. , 2008, The Journal of allergy and clinical immunology.

[55]  A. Kaplan,et al.  Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[56]  James Brian Byrd,et al.  Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema , 2008, Hypertension.

[57]  M. Mohammadi,et al.  An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio‐oedema , 2007, Clinical and experimental immunology.

[58]  H. Farkas,et al.  C1-inhibitor (C1-INH) autoantibodies in hereditary angioedema. Strong correlation with the severity of disease in C1-INH concentrate naïve patients. , 2007, Molecular immunology.

[59]  S. Cichon,et al.  Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. , 2006, American journal of human genetics.

[60]  K. Bork,et al.  Hereditary angioedema: new findings concerning symptoms, affected organs, and course. , 2006, The American journal of medicine.

[61]  J. Rouleau,et al.  A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. , 2005, American journal of human genetics.

[62]  T. González-Quevedo,et al.  CA 125: Marker of serosal inflammation in hereditary angioedema? , 2005, Allergy.

[63]  D. Wagner,et al.  A Direct Role for C1 Inhibitor in Regulation of Leukocyte Adhesion 1 , 2005, The Journal of Immunology.

[64]  G. Kojda,et al.  Increased C-reactive protein in ACE-inhibitor-induced angioedema. , 2005, British journal of clinical pharmacology.

[65]  H. Farkas,et al.  Sex hormones in hereditary angioneurotic oedema , 2004, Clinical endocrinology.

[66]  M. Cicardi,et al.  Autoantibodies and Lymphoproliferative Diseases in Acquired C1-Inhibitor Deficiencies , 2003, Medicine.

[67]  M. Gompels,et al.  Misdiagnosis of hereditary angio‐oedema type 1 and type 2 , 2003, The British journal of dermatology.

[68]  M. Cicardi,et al.  Bradykinin and the pathophysiology of angioedema. , 2003, International immunopharmacology.

[69]  A. Kaplan,et al.  Activation of the bradykinin-forming cascade on endothelial cells: a role for heat shock protein 90. , 2002, International immunopharmacology.

[70]  W. Simmons,et al.  Dipeptidyl Peptidase IV Activity in Patients With ACE-Inhibitor-Associated Angioedema , 2002, Hypertension.

[71]  M. Gompels,et al.  A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency. , 2002, Journal of clinical pathology.

[72]  H. Farkas,et al.  Ultrasonography in the diagnosis and monitoring of ascites in acute abdominal attacks of hereditary angioneurotic oedema , 2001, European journal of gastroenterology & hepatology.

[73]  M. Cicardi,et al.  Pathogenetic and clinical aspects of C1 inhibitor deficiency. , 1998, Immunobiology.

[74]  M. Cicardi,et al.  Plasma bradykinin in angio-oedema , 1998, The Lancet.

[75]  P. Mannucci,et al.  Activation of the coagulation cascade in C1-inhibitor deficiencies. , 1997, Blood.

[76]  M. Cicardi,et al.  Relevance of lymphoproliferative disorders and of anti‐C1 inhibitor autoantibodies in acquired angio‐oedema , 1996, Clinical and experimental immunology.

[77]  T. Mollnes,et al.  Activation of the Complement, Coagulation, Fibrinolytic and Kallikrein–Kinin Systems During Attacks of Hereditary Angioedema , 1996, Immunopharmacology.

[78]  M. Cicardi,et al.  Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. , 1996, Immunopharmacology.

[79]  T. Mollnes,et al.  C1 Inhibitor and Diagnosis of Hereditary Angioedema in Newborns , 1994, Pediatric Research.

[80]  A. Davis,et al.  Hereditary angioneurotic oedema: characterization of plasma kinin and vascular permeability‐enhancing activities , 1994, Clinical and experimental immunology.

[81]  J. Alsenz,et al.  Autoantibody-mediated acquired deficiency of C1 inhibitor. , 1987, The New England journal of medicine.

[82]  D. Ogston,et al.  Blood levels of proteinase inhibitors in pregnancy , 1982, British journal of obstetrics and gynaecology.

[83]  H. Oflaz,et al.  There is an increased risk of atherosclerosis in hereditary angioedema. , 2012, International immunopharmacology.

[84]  A. Kaplan,et al.  Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[85]  T. Buclin,et al.  Is dipeptidylpeptidase IV the missing link in angiotensin-converting enzyme inhibitor--induced angioedema? , 2008, Hypertension.

[86]  F. Marceau,et al.  The kallikrein-kinin system: current and future pharmacological targets. , 2005, Journal of pharmacological sciences.

[87]  A. Eerenberg,et al.  Generation of plasmin during acute attacks of hereditary angioedema. , 1993, The Journal of laboratory and clinical medicine.

[88]  Z. Oltvai,et al.  C1 inhibitor deficiency: molecular and immunologic basis of hereditary and acquired angioedema. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[89]  B. Wüthrich,et al.  Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema--evidence of a functionally critical level of C1-inhibitor concentration. , 1984, Complement.